Menu
← Oncology Approval Tracker
FDA DECISION ·
Besponsa
inotuzumab ozogamicin · Pfizer
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Children aged 1 year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.
LAMPGEN ANALYSIS
Why it matters
The CD22-directed antibody–drug conjugate expanded into a pediatric salvage setting.
What research teams should watch
Confirm CD22 expression and communicate cumulative exposure and hepatic veno-occlusive disease risk to transplant teams.
PRIMARY RECORDS